Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new pharmacologically therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing LDLR degradation and preventing LDLR recirculation to the cell surface. Moreover, PCSK9 inhibitors have been approved for patients with either familial hypercholesterolemia or atherosclerotic cardiovascular disease, who require additional reduction of LDL-C. In addition, PCSK9 inhibition combined with statins has been used as a new approach to help reduce LDL-C levels in patients with either statin intolerance or unattainable LDL goal. This review will discuss the emerging anti-PCSK9 therapies in the regulation of cholesterol metabolism and atherosclerosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2018.05.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Myocardial Infarction Due to Spontaneous Coronary Artery Dissection at 36 Weeks of Pregnancy: A Case Report.
Ann Ital Chir
March 2025
Department of Medical, Surgical, Neurologic, Metabolic and Ageing Sciences, Unit of Colorectal Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Aim: Acute myocardial infarction in pregnancy (pAMI) is a rare event that is often caused by non-classical factors rather than atherosclerosis. The management of such complications requires a multidisciplinary team, and it is important to bring together the specialties involved to ensure that these teams are coordinated and ready to respond. The management of pAMI poses unique challenges because it requires consideration of both maternal and fetal well-being.
View Article and Find Full Text PDFTanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs/NF-κB signaling pathway.
Int Immunopharmacol
March 2025
Department of Cardiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address:
Objectives: Tanshinone IIA (Tan IIA) exhibits therapeutic potential for atherosclerosis (AS) and hepatic steatosis (HS). The study aims to explore the mechanisms underlying the anti-atherosclerosis and anti-hepatic steatosis effects of Tan IIA.
Methods: The LDLRmice were divided into control, model, low/high Tan IIA and atorvastatin group, which fed with High-fat diet to build NAFLD-associated AS model, then administrated with 0.
Liver and atherosclerotic risk of alcohol consumption in patients with metabolic dysfunction-associated Steatotic Liver Disease.
Atherosclerosis
March 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Background/purpose: A new disease name, "Steatotic Liver Disease (SLD)" was proposed in 2023. Within this algorithm, combined metabolic and alcoholic liver disease (MetALD) was named as a new specific subgroup. The clinical profiles and outcomes of MetALD patients are unknown.
View Article and Find Full Text PDFHomocysteine Promotes the Pathogenesis of Atherosclerosis through the Circ-PIAS1-5/miR-219a-2-3p/TEAD1 Axis.
Adv Sci (Weinh)
March 2025
NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, 750004, China.
Previous studies have established a possible link between hyperhomocysteinemia (HHcy) and dyslipidemia. Circular RNAs (circRNAs) play important regulatory roles in the development of atherosclerosis. However, the biological functions and potential molecular mechanisms of circRNAs in HHcy-induced lipid accumulation leading to atherosclerosis are still unclear.
View Article and Find Full Text PDFAssociations between the cardiometabolic index and atherosclerotic cardiovascular disease acorss different glucose metabolism statuses: insights from NHANES, 1999-2020.
Lipids Health Dis
March 2025
Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Hospital, No.5 Haiyuncang Hutong, Dongcheng District, Beijing, 100700, China.
Background: The cardiometabolic index (CMI) serves as a significant marker of diabetes mellitus (DM) and may predict the potential for cardiovascular disease development. Nevertheless, the correlation between CMI and atherosclerotic cardiovascular disease (ASCVD) among individuals exhibiting varying glucose metabolism statuses (GMS) continues to be unclear.
Methods: Overall, 24,006 individuals aged 20 and above were enrolled in the research, drawn from the National Health and Nutrition Examination Survey (NHANES) database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!